On July 31, AstraZeneca and Merck & Co. jointly announced that their PARP inhibitor Lynparza, in combination with Abiraterone and prednisolone, has been approved in China for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry germline or somatic BRCA mutations (gBRCAm or sBRCAm).
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in HRR, such as mutations in BRCA1 and/or BRCA2. Inhibition of PARP with Lynparza leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.
This approval was primarily based on the subgroup analysis results from the global and Chinese cohorts of the PROpel Phase III trial. PROpel is a randomized, double-blind, multicenter Phase III clinical trial evaluating the efficacy, safety, and tolerability of Lynparza in combination with Abiraterone and prednisolone compared to placebo plus Abiraterone and prednisolone in male patients with mCRPC who have not received prior chemotherapy or novel hormonal therapy (NHA) at the mCRPC stage.
Data from the global cohort of patients with BRCA mutations showed that Lynparza in combination with Abiraterone demonstrated a clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to Abiraterone monotherapy. Subgroup analysis of patients with BRCA mutations in the global cohort revealed that Lynparza combined with Abiraterone reduced the risk of disease progression or death by 76% and the risk of death by 70%. The median rPFS and median overall survival (OS) in the Lynparza plus Abiraterone group had not yet been reached, whereas the median rPFS and median OS in the Abiraterone monotherapy group were 8 months and 23 months, respectively.
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Post time: Aug-07-2025